RARE
Ultragenyx
NASDAQ: RARE · HEALTHCARE · BIOTECHNOLOGY
$24.18
-1.43% today
Updated 2026-04-29
Market cap
$2.38B
P/E ratio
—
P/S ratio
3.53x
EPS (TTM)
$-5.83
Dividend yield
—
52W range
$18 – $42
Volume
2.0M
Ultragenyx (RARE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-5.83M | $-12.50M | $-31.20M | $-44.63M | $-105.98M | $-160.97M | $-253.84M | $-290.57M | $-345.38M | $-132.22M | $-338.69M | $-380.46M | $-474.81M | $-414.19M | $-466.00M |
| Capital expenditures | $548000.00 | $1.09M | $407000.00 | $2.15M | $4.96M | $10.19M | $2.79M | $4.08M | $24.83M | $43.91M | $73.09M | $146.12M | $46.77M | $7.49M | $6.00M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $254000.00 | $891000.00 | $657000.00 | $5.39M | $24.88M | $48.31M | $68.01M | $80.11M | $82.00M | $85.73M | $104.95M | $130.38M | $135.21M | $158.03M | $153.00M |
| Free cash flow | $-6.37M | $-13.60M | $-31.61M | $-46.78M | $-110.93M | $-171.16M | $-256.64M | $-294.64M | $-370.21M | $-176.13M | $-411.79M | $-526.59M | $-521.57M | $-421.68M | $-472.00M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $4.35M | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $16.90M | $69.25M | $67.55M | $-60.63M | $12.96M | $320.88M | $288.93M | $-415.51M | $-170.91M | — | — | — |